Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642942 | 0.84 | FFAR3 (0.32) | — | |
| SCHEMBL10990279 | 0.83 | ALDH1A1 (0.35) | ALDH1A1TSHRGAASMN1; SMN2POLB | |
| SCHEMBL5435193 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TSHRGAASMN1; SMN2POLB | |
| SCHEMBL14435631 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TSHRGAASMN1; SMN2POLB | |
| SCHEMBL30191841 | 0.77 | ALDH1A1 (0.35) | ALDH1A1TSHRGAASMN1; SMN2POLB | |
| SCHEMBL11207858 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TSHRPOLB | |
| SCHEMBL669392 | 0.74 | MEN1 (0.34) | ALDH1A1TSHRGAASMN1; SMN2POLB | |
| SCHEMBL7713090 | 0.74 | ALDH1A1 (0.33) | ALDH1A1TSHRGAASMN1; SMN2POLB | |
| SCHEMBL7399965 | 0.73 | MAPK1 (0.33) | NPC1NPSR1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL7399963 | 0.73 | MAPK1 (0.33) | NPC1NPSR1ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004065361-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | NPC1 1795/4885NPSR1 280/4885ALDH1A1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.